扩张型心肌病患者神经内分泌抑制治疗调查分析

摘要

Objective To investigate the usage of neuroendocrine inhibitors in patients with dilated cardiomy-opathy. Methods The usage of three types of neuroendocrine inhibitors, including angiotensin converting enzyme in-hibitor (ACEI) or angiotensinⅡreceptor blocker (ARB),β-blocker and aldosterone receptor antagonist (MRA), in 332 cases of patients with dilated cardiomyopathy, who admitted to our hospital from January 2014 to December 2015, were retrospectively analyzed. Results In 332 cases, the usage rates of ACEI/ARB,β-blocker and MRA were respectively 85.9%, 74.7%and 94.4%. 56.9%of patients accepted the combination therapy of three types of neuroendocrine inhibi-tors. The rates of reaching standard dose of ACEI/ARB, β-blocker and MRA were respectively 69.3%, 42.0% and 100.0%. Conclusion The usage rates of three types of neuroendocrine inhibitors in dilated cardiomyopathy patients are high, but the combination use and the rates of reaching standard dose of ACEI/ARB andβ-blockers are somewhat low.%目的：调查某院扩张型心肌病患者神经内分泌抑制治疗的情况。方法选取无锡市人民医院2014年1月至2015年12月收治的扩张型心肌病患者，对患者三类神经内分泌抑制剂即血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体拮抗剂(ARB)、β-受体阻滞剂(βB)和醛固酮受体拮抗剂(MRA)的使用情况进行回顾性分析。结果332例患者中，ACEI/ARB、β-受体阻滞剂和MRA的使用率分别为85.9%、74.7%、94.7%，三类药物联合使用率为56.9%。三类药物均在推荐用量内给药，剂量达标率ACEI/ARB 69.3%、β-受体阻滞剂42.0%、MRA 100.0%。结论我院三类神经内分泌抑制剂在扩张型心肌病患者中使用率较高，但ACEI/ARB和β-受体阻滞剂的联合用药率及剂量达标率偏低。